Check out coverage of the key presentations, and get direct access to expert perspectives, straight from the floor in Los Angeles.
Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder
View More
PER® Psychiatry Summit
November 7, 2024
View More
Join Us for COPE CE Sessions In-Person or Virtually
Thursday, November 7, 2024 - Friday, November 8, 2024
Register Now!
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis - Current Treatment and Emerging Con...
November 12, 2024
Register Now!
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
19th Annual New York Lung Cancers Symposium®
November 16, 2024
Register Now!
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Defining the Characteristics of Breakthrough Invasive Fungal Infections in Hematologic Disorders
October 31st 2024This systematic review focuses on breakthrough invasive fungal infections (bIFIs) in patients with high-risk hematological cancers, like acute leukemia, or those who have undergone stem cell transplants. Despite prophylactic antifungal treatments (usually with voriconazole or posaconazole), bIFIs remain challenging due to their complexity and high mortality rates.
From Poultry to Public Health: Understanding the H5N1 Threat
October 29th 2024Veterinary and public health officials share the important roles of surveillance and prevention strategies, insights on the virus's transmission pathways, historical context, the One Health approach, and highlights effective precautionary measures to mitigate H5N1 risks.
INSTIs and Cardiovascular Outcomes: More Complexity
October 28th 2024The significance of antiretroviral therapy (ART) has been a game changer for people living with HIV (PLWH). Still, there are some cardiovascular risks associated with different ART classes—particularly protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and integrase strand transfer inhibitors (INSTIs). Authors review a piece in the literature around this area of study.
Top 5 Infectious Disease News Stories Week Of October 18-25
October 26th 2024Experts highlighted research showing that even mild COVID can result in cognitive impairment including brain fog and IQ decline, the FDA approved Pfizer's RSV vaccine for adults aged 18 to 59, E coli outbreak linked to McDonald's Quarter Pounders, and more.
Day 1 Recap from CDC ACIP Meeting: COVID, Pneumococcal, Influenza, and RSV Vaccine Recommendations
Important vaccine updates, including a second COVID-19 vaccine dose for adults 65 and older and immunocompromised individuals, a pneumococcal vaccine for adults aged 50 and older, and more.
First-Hand Insights into Treating Hepatitis C in Pregnancy
October 17th 2024Catherine Chappell, MD, MSc, presents what we know so far, highlighting the safety and effectiveness of direct-acting antivirals, the importance of shared decision-making, and the need for patient-provider discussions to ensure informed choices about care.
Investigational Antibiotic Shows Efficacy, Safety in Late Stage Trial for Uncomplicated Gonorrhea
October 16th 2024A phase 3 therapy, zoliflodacin, has shown to be noninferior in a late stage trial. The therapy's manufacturer, Innoviva Speciality Therapeutics, is presenting data at this week's ID Week. The company's CMO David Altarac, MD, offers some insights on the therapy and the timeline for filing the paperwork for prospective FDA approval.